CTLA4 and hypophysitis: Despite these limitations, we were able to evaluate the long-term follow-up of a large cohort of patients with IR-hypophysitis and to provide new data on the clinical differences between anti-PD-(L)1 and anti-CTLA-4 (mono and combination) therapy induced hypophysitis.